Molecular Sensoring Technology Co. Ltd. (Molsentech) has developed a diagnostic platform using semiconductor chips with biosensors for COVID-19 testing. The platform could deliver a result anywhere from three to 30 minutes, with accuracy compatible to the polymerase chain reaction (PCR) tests.
HKSH Medical Group (HKSH) has adopted droplet digital polymerase chain reaction (ddPCR) for minimal residual disease (MRD) monitoring to track the status of patients with leukemia.
Tianjin Usights Ophthalmology Technology Co. Ltd.’s ophthalmic fiberoptic microcatheter system has been approved by the NMPA for marketing for minimally invasive glaucoma surgery (MIGS) in China. Tianjin, China-based Usights claims this is the first homegrown products for MIGS in China that has been approved.
Rainmed Medical Ltd.'s coronary angiography-derived fractional flow reserve system (caFFR system) was approved by Australia’s TGA for precision diagnosis of coronary artery diseases.
Sino Medical Sciences Technology Inc. received marketing approval from China’s NMPA for its drug eluting stent system to improve vascular stenosis in patients with localized ischemic heart disease. The product is designed to improve the speed of wound healing and accelerate the recovery of vascular endothelium after stent implantation. It fits vessels with a diameter of 2.25 mm to 4.00 mm and a lesion length of less than or equal to 40 mm.
Aim Biotech Pte. Ltd. has launched a lab tool that can closely model human disease. The organic system can add vascularization and immune competence to organoids, spheroids and tumor biopsies. This allows for the creation of a more defined and tunable microenvironment that more closely emulates the complexity of human physiology.
Shenzhen Proxinse Medical Technology Co. Ltd. raised an undisclosed amount in a series A financing to develop endoscope-related products. This round of financing was led by Guangdong Technology Financial Group Co. Ltd.